In light of antipsychotic treatment-emergent cardiometabolic adverse events, 4 several government reports called for efforts to improve pediatric psychotropic medication oversight in state Medicaid agencies. 5 Such efforts include telephone access lines through which prescribers can consult with psychiatrists, letters to prescribers, and, recently, age-restricted prior authorization policies, which require clinicians to obtain preapproval from Medicaid agencies to prescribe atypical antipsychotics to children younger than a certain age as a condition for coverage. A distinct subset of these age-restricted prior authorization policies, classified as peer review policies, brings clinical expertise into the review process by requiring contracted clinicians (peer reviewers) to adjudicate antipsychotic prescriptions for children. Several studies in adults have shown Medicaid prior authorization policies can reduce antipsychotic use. To facilitate empirical evaluation of these policies in youth, we identified state Medicaid programs with a prior authorization policy in effect for pediatric atypical antipsychotic prescribing and characterized these policies according to agerestriction criteria and whether a peer review process was present.
Methods | We reviewed antipsychotic-related Medicaid prior authorization policies for youth (<18 years) in 50 states plus the District of Columbia between June 2013 and August 2014. Two authors (I.S., M.B.) extracted information from web documents relating to prior authorization, including a basic policy description, the date it went into effect, the professionals involved in performing the review, and the age-restriction criteria. Incomplete or unclear information from 43 agencies was supplemented by email exchange. All authors agreed on interpretation of the collected data. Varies by drug Clinical peer review is required for children younger than 6 y regardless of drug entity; subsequent authorization is needed by the pharmacy for clozapine (age <6 y), olanzapine (age <6 y), olanzapine-fluoxetine (age <6 y), paliperidone (age <12 y), risperidone (age <2 y), quetiapine (age <6 y), ziprasidone (age <6 y), and other atypical antipsychotics (age <18 y) 
